Impact of SF3B1 mutation in myelofibrosis

Click to increase image sizeClick to decrease image size

Disclosure statement

SV received research grant/funding from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Genentech, Blueprint, Novartis, Sierra, Pharma Essentia, Astrazeneca, Italfarmaco, and Protagonist Therapeutics; received consulting fees from Constellation, Sierra, Incyte, Novartis, Celgene, and Bristol Myers Squibb. NP received consulting fees/honoraria from Pacylex, Celgene, Stemline, Incyte, Novartis, Mustang Bio, Roche Diagnostics, and LFB and research funding from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, Affymetrix, and Sager Strong Foundation. GMB received research funding from IFM Therapeutics. HK received research grants and honoraria from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer and Sanofi; honoraria from Actinium (Advisory Board), Adaptive Biotechnologies, Aptitude Health, Bio Ascend, Delta Fly, Janssen Global, Oxford Biomedical and Takeda Oncology. PB recived honoraria from Incyte, BMS, CTI BioPharma, Sierra Oncology, Constellation (Morphosys), Blueprint Medicines, Novartis, Pharma Essentia, Karyopharm, and Kartos, and research support from Incyte, BMS, CTI BioPharma, Cogent, Blueprint Medicines, Pfizer, Astellas, NS Pharma, Promedior, Kartos and Constellation (Morphosys).

The other authors declare no relevant conflicts of interest.

Data sharing

Data available from corresponding author on request.

Additional information

Funding

This work was supported, in part, by the MD Anderson Cancer Center Support Grant, P30 CA016672, from the National Cancer Institute (National Institutes of Health).